Summit Therapeutics SMMT
NASDAQ SMMT
$16.40 +0.92 (+5.94%)
As of: Sep 29, 2026 · 3:59 PM EDT

Summit Therapeutics (SMMT) Debt Ratio (2021 - 2024)

Updated

Summit Therapeutics' (SMMT) Debt Ratio was 0.05 for Q3 2024, down 89.4% from 0.46 a year earlier and down 83.3% from the prior quarter.

Analysis

Summit Therapeutics (SMMT) Debt Ratio (2021 - 2024) Analysis & Trends

For FY2023, Debt Ratio at Summit Therapeutics was 0.49, down 36.4% from FY2022.

  • By year, Debt Ratio came in at 0.77 in FY2022.
  • The Q3 2024 figure ranks as the lowest quarterly Debt Ratio in data going back to Q1 2021.
  • Year over year, Debt Ratio gained in three of the last six quarters, with growth averaging 4.9%.
  • Per Business Quant data, the three quarters before Q3 2024 came in at 0.29 (Q2 2024), 0.57 (Q1 2024) and 0.49 (Q4 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 0.24
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 0.52
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 0.42
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 0.31
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 0.00
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 0.60
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Summit Therapeutics 12.28 Bn 10.04 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 0.05
Jun 30, 2024 0.29
Mar 31, 2024 0.57
Dec 31, 2023 0.49
Sep 30, 2023 0.46
Jun 30, 2023 0.42
Mar 31, 2023 0.39
Dec 31, 2022 0.77
Jun 30, 2022 0.26
Mar 31, 2022 0.22
Mar 31, 2021 0.39
API Access

Summit Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=SMMT&period=max&api_key=YOUR_API_KEY